About this trial
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .
Eligibility criteria
Qualifiers
Males 18 -89 undergoing HoLEP
Willing to sign the Informed Consent Form
Able to read, understand, and complete patient questionnaires.
Disqualifiers
Allergy or hypersensitivity to furosemide or other loop diuretic
Anuric patients or patients with liver failure
Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP
Anticipated need for perineal urethrostomy at the time of HoLEP
Trial design
Treatments tested in this trial
- Furosemide